Treatment of a population based sample of men diagnosed with testicular cancer in the United States

Abstract

Objectives-Testicular cancer is the most common cancer in men age 25 to 35 years. We examined therapy, compliance with guidelines, and survival in a population based sample of men newly diagnosed with testicular cancer.Materials and Methods-We analyzed the National Cancer Institute's (NCI) patterns of care data on 702 men diagnosed with testicular cancer in 1999. These studies supplement routine data collection by verifying therapy with the patients' treating physician. Follow-up for vital status was available through December 31, 2004.Results-The majority of the men with localized seminoma were diagnosed while their cancer was localized and more than 80% of received orchiectomy with radiation. For men with seminoma and nonseminoma (NSGCT) tumors the percent receiving chemotherapy increased markedly as stage increased. More than 90% of men with regional and distant NSGCT received chemotherapy. Less than 25% of men with localized NSGCT received orchiectomy and retroperitoneal lymph node dissection (RPLND), about 40% had surveillance following an orchiectomy alone and the other third received orchiectomy and chemotherapy.Conclusions-The majority of these patients received therapy consistent with guidelines. While there was no significant difference in the use of RPLND in men with localized NSGCT by geographic region, chemotherapy use varied widely. Over 90% of men with localized or regional disease diagnosed in 1999 were alive at the end of 2004. The excellent survival rates point to the need to monitor for late effects of therapy.

Clinical presentation features of testicular cancer in public hospitals in the Autonomous Community of Madrid, Spain

“…In this same series, surgery was combined with chemotherapy (carboplatin) in 68% of cases, a slightly higher figure than that of our experience which stands at 47.4%. We coincided less with Osswald et al 29 since they treated seminomas in stage I with surgery and radiotherapy in over 80% of cases, which only occurred in 17.5% of cases in our series.…”

Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma

“…These risks have a direct bearing on current management strategy in stage I seminoma of the testis since adjuvant radiotherapy is still widely used (Osswald et al , 2009; Vossen et al , 2012). …”

Testicular Germ-Cell Tumours: A Descriptive Analysis of Clinical Characteristics at First Presentation

“…It is well-established knowledge that nonseminoma presents more often with metastatic spread than seminoma [11]. However, in light of the repeatedly documented shifting of stages over time [12, 13], there is little data regarding the distribution of clinical stages (CS) in a modern unselected series of primary GCT patients.…”